Form 4 for KROS Keros Therapeutics, Inc.
Accepted 2023-04-11 00:00:00 ET · period of report 2023-04-08 · accession 0001209191-23-023991 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-04-11 | 2023-04-08 | KROS | Seehra Jasbir | CEO, Dir | M - OptEx | $0.48 | +4,000 | 252.9K | +2% | +$1,920 |
| D | 2023-04-11 | 2023-04-08 | KROS | Seehra Jasbir | CEO, Dir | M - OptEx | $0.00 | -4,000 | 45.1K | -8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-04-08 | M | A | 4,000 | $0.48 | 252,856 | D | — | — | |
| 2 | Derivative | Employee Stock Option (right to buy) | 2023-04-08 | M | D | 4,000 | $0.00 | 45,087 | D | $0.48 · — to 2029-06-18 | 4,000 Common Stock | (F1) Fully vested and exercisable. |